Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Vile

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Human Gene Therapy|September 10, 1996
Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunityH Chong, G Hutchinson, I R Hart, et al.
British Journal of Cancer|October 29, 1998
Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumoursH Chong, G Hutchinson, I R Hart, et al.
Virology|August 1, 1992
Identification of a generalised packaging sequence for D-type retroviruses and generation of a D-type retroviral vectorR G Vile, M Ali, E Hunter, et al.
Biochemical Society Transactions|May 1, 1997
Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cellsR G Vile, R M Diaz, S Castleden, et al.
Journal of Virology|January 7, 1998
Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanomaR M Diaz, T Eisen, I R Hart, et al.
Immunology|March 11, 2000
Heat shock proteins refine the danger theoryS M Todryk, A A Melcher, A G Dalgleish, et al.
Gene Therapy|May 14, 1998
Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunityH Chong, S Todryk, G Hutchinson, et al.
Expert Opinion on Investigational Drugs|November 28, 2000
Cancer gene therapy: developments to 2000A R Bateman, K J Harrington, A A Melcher, et al.
Gut|November 21, 1998
Can immunotherapy by gene transfer tip the balance against colorectal cancer?S M Todryk, H Chong, R G Vile, et al.
Nature Medicine|May 19, 1998
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expressionA Melcher, S Todryk, N Hardwick, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Human Gene Therapy|September 10, 1996
Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunityH Chong, G Hutchinson, I R Hart, et al.
British Journal of Cancer|October 29, 1998
Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumoursH Chong, G Hutchinson, I R Hart, et al.
Virology|August 1, 1992
Identification of a generalised packaging sequence for D-type retroviruses and generation of a D-type retroviral vectorR G Vile, M Ali, E Hunter, et al.
Biochemical Society Transactions|May 1, 1997
Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cellsR G Vile, R M Diaz, S Castleden, et al.
Journal of Virology|January 7, 1998
Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanomaR M Diaz, T Eisen, I R Hart, et al.
Immunology|March 11, 2000
Heat shock proteins refine the danger theoryS M Todryk, A A Melcher, A G Dalgleish, et al.
Gene Therapy|May 14, 1998
Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunityH Chong, S Todryk, G Hutchinson, et al.
Expert Opinion on Investigational Drugs|November 28, 2000
Cancer gene therapy: developments to 2000A R Bateman, K J Harrington, A A Melcher, et al.
Gut|November 21, 1998
Can immunotherapy by gene transfer tip the balance against colorectal cancer?S M Todryk, H Chong, R G Vile, et al.
Nature Medicine|May 19, 1998
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expressionA Melcher, S Todryk, N Hardwick, et al.
Pageof 9